---
title: "121 Growth-stage Healthtech Investors in the US (Nov 2026)"
last_updated: "2026-11-07"
rows: "121"
free_rows: "25"
source: "SEC Form D filings and our own research"
canonical: "https://theinvestordatabase.com/lists/growth-healthtech-investors-us/"
---

# 121 growth-stage healthtech investors in the US

We list 121 growth-stage healthtech investors in the US as of November 2026: 119 have an SEC filing on file and 2 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The cities with the most head offices on this list are New York (20), San Francisco (8) and Menlo Park (7).

- 121 investors
- 61 with a fund filing or dated deal in the last 12 months
- $125M median fund size on file (SEC Form D, 77 firms)
- 679 named decision-makers on file

## First 25 of 121 growth-stage healthtech investors in the US

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Town Hall Ventures | VC firm | New York, NY | Growth | Healthtech, Impact, Medtech | New deal, Sep 2026 | $400M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/town-hall-ventures/ |
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Healthtech, Biotech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Healthtech, Biotech, Medtech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/mvm-partners-llp/ |
| Alpha Partners | VC firm | New York, NY | Series B, Growth | Healthtech, AI, Developer Tools, Cybersecurity | New fund, Oct 2026 | $200M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/alpha-partners/ |
| Elsewhere Partners | VC firm | Austin, TX | Growth | Healthtech, Cybersecurity, AI, SaaS | New deal, Jul 2026 | $285M (SEC Form D, 2023) | 2026-11-05 | https://theinvestordatabase.com/investors/elsewhere-partners/ |
| New Science Ventures | VC firm | United States | Seed, Growth, Late stage | Healthtech, Deep Tech, AI, Semiconductor | Portfolio news, Oct 2026 | $1.0B (own site) | 2026-11-05 | https://theinvestordatabase.com/investors/new-science-ventures/ |
| Greycroft | VC firm | New York, NY | Series A, Series B, Growth | Healthtech, AI, Industrial Tech, Defense Tech | New deal, Oct 2026 | $600M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/greycroft/ |
| Khosla Ventures | VC firm | Menlo Park, CA | Pre-seed, Seed, Series A, Growth | Healthtech, AI, Consumer, B2B | New fund, Aug 2026 | $1.9B (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/khosla-ventures/ |
| JSTAR Capital | VC firm | Austin, TX | Growth | Healthtech, AI, Fintech, Medtech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/jstar-capital/ |
| Temper | VC firm | Sugar Land, TX | Growth | Healthtech, Proptech, AI, Defense Tech | New fund, Jul 2026 | $25M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/temper/ |
| FTV Capital | VC firm | San Francisco, CA | Growth | Healthtech, Fintech, SaaS, B2B | New fund, Jul 2026 | $11.9B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/ftv-capital/ |
| Transformation Capital | VC firm | Boston, MA | Growth | Healthtech, Medtech | New fund, Sep 2026 | $800M (SEC Form D, 2022) | 2026-11-04 | https://theinvestordatabase.com/investors/transformation-capital/ |
| Echo Health Ventures | Corporate VC | Durham, NC | Growth | Healthtech, Medtech | Portfolio news, Sep 2026 | $518M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/echo-health-ventures/ |
| NewVale Capital | VC firm | Boulder, CO | Growth | Healthtech, Biotech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/newvale-capital/ |
| Quartus | VC firm | New York, NY | Growth | Healthtech, AI, B2B, Edtech | New fund, Sep 2026 | $150M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/quartus/ |
| Lightspeed Venture Partners | VC firm | Menlo Park, CA | Seed, Series A, Series B, Growth | Healthtech, AI, Gaming, SaaS | New fund, Jul 2026 | $1.2B (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/lightspeed-venture-partners/ |
| Audere | VC firm | Austin, TX | Growth | Healthtech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/audere/ |
| Ansa | VC firm | New York, NY | Series A, Series B, Growth | Healthtech, AI, Cybersecurity, Media | New fund, May 2026 | $200M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/ansa/ |
| HLM Investment Partners | VC firm | Waltham, MA | Growth | Healthtech, Medtech | New fund, Aug 2026 | $61M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/hlm-investment-partners/ |
| SignalFire | VC firm | San Francisco, CA | Seed, Series A, Series B, Growth | Healthtech, AI, Developer Tools, B2B | New fund, May 2026 | $357M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/signalfire/ |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Healthtech, Biotech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/arcventis-health-partners/ |
| Portfolia | Fund manager | San Mateo, CA | Growth | Healthtech, Media, Fintech, Climate Tech | New fund, Apr 2026 | $6M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/portfolia/ |
| Bioventures Investors | VC firm | Westborough, MA | Growth | Healthtech, Future of Work, Fintech, Medtech | New deal, Apr 2025 | $350M (SEC Form D, 2020) | 2026-11-05 | https://theinvestordatabase.com/investors/bioventures-investors/ |
| TVC Capital | VC firm | La Jolla, CA | Growth | Healthtech, SaaS, B2B, AI | Portfolio news, Jan 2025 | $308M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/tvc-capital/ |
| Coefficient Capital | VC firm | New York, NY | Growth | Healthtech, Food and Beverage, Logistics, Consumer | New deal, Jun 2026 | $286M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/coefficient-capital/ |

You are seeing 25 of 121. The full list adds 96 more investors and 679 named decision-makers.

Get all 121 investors and 679 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/growth-healthtech-investors-us
This page: https://theinvestordatabase.com/lists/growth-healthtech-investors-us/

## Method and limits
- Source: 119 of the 121 rows carry an SEC filing (Form D or Form ADV). All 121 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states healthtech and digital health as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 121 rows: stage 121, sector 121, fund size 106, website 121. In the paid file: named decision-makers on 115 rows, firm email on 44, LinkedIn page on 66, check size on 12.

## Questions
### How many growth-stage healthtech investors in the US are there?
We list 121 as of November 2026. 61 of the 121 have a fund filing or a dated deal in the last 12 months. The cities with the most are New York (20), San Francisco (8) and Menlo Park (7).

### Which growth-stage healthtech investors in the US raised a new fund in the last 12 months?
41 of the 121 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), IVP: Venture capital for the Exceptional (Oct 2026) and K5 Global (Oct 2026).

### What is the typical fund size of growth-stage healthtech investors in the US?
The median fund size on file for this list is $125M, across the 77 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 44 do not disclose a size there.

### How do I contact growth-stage healthtech investors in the US?
The paid file holds 679 named decision-makers across 115 of these 121 and a firm email for 44. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on growth-stage healthtech investors in the US come from?
119 of the 121 rows have an SEC filing on file (Form D or Form ADV) and 2 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.